OR WAIT null SECS
Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.
December 07, 2016
Previous hesitation by pharma industry to use cocrystals may change with FDA’s new guidance that classifies cocrystals APIs.
December 02, 2016
Non-precious-metal catalysts are increasingly employed for commercial API synthesis.
November 15, 2016
Pressures to accelerate current and next-gen therapies are challenging traditional microbiological testing models.
November 02, 2016
New catalysts show promise for pharmaceutical intermediate and API synthesis.
FDA redefines cocrystals as APIs and not drug-product intermediates.
October 05, 2016
A simpler, cost-effective method for the preparation of fluorolactams may be suitable for scale-up.